Discussion
arrhythmia, stroke, OSA, T2DM, hypoglycemic, Nausea, cardiovascular and cerebrovascular diseases, hypertension, weight loss, diabetes
ARRHYTHMIA, SLEEP APNEA, STROKE, CORONARY HEART DISEASE, HEART FAILURE, HYPERTENSION, DIABETES
Liraglutide is a hypoglycemic agent used to treat T2DM. It is a glucagon-like peptide-1 receptor agonist (GLP-1RA) and can also be used in weight loss therapy [Several large studies in patients with diabetes have found that liraglutide improves blood sugar control and leads to significant weight loss [The SCALE sleep apnea study showed weight loss and improved AHI scores in the liraglutide group, which was consistent with the conclusions of this study [OSA is a risk factor for hypertension, coronary heart disease, arrhythmia, heart failure, stroke, and other cardiovascular and cerebrovascular diseases [GLP-1 agonists and analogs have been reported to be well tolerated. Nausea is the most common symptom of discomfort during early liraglutide treatment [Although these results are novel, there are limitations to our study that need to be considered. First, despite being a two-center study, the sample size was not large, which limits the ability to generalize the findings. Second, follow-up time was limited and the effects on lipids, blood sugar, and other indicators need to be confirmed by longer term follow-up studies. Third, our findings cannot be generalized to patients with mild OSA because only patients with severe OSA were enrolled.